Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

UPDATE REGARDING THE ASARINA PHARMA SHARE

The Asarina Pharma shares were delisted from NASDAQ First North in October 2024 after an Extraordinary General Meeting decided to liquidate the company. After the delisting, it is no longer possible to trade the Asarina Pharma shares.

In February 2025, Asarina Pharma sold all its IP assets to Relmada Therapeutics, a neurology company in the US (see press release on this website).

After the sale of the IP assets to Relmada, the company is winding its remaining operations and paying its creditors. If there is cash remaining at the end of the liquidation, it will be distributed to the shareholders.

ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023 2024-02-27 08:30 Regulatory Interim

(Stockholm, 27 February 2024) Asarina Pharma (“the Company”) today releases its Second Half-Year and Year-End Report for 2023. The full Report...

Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB 2023-11-30 10:30 Regulatory

Asarina Pharma AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB. The Company has entered into an...

Asarina Pharma updates on partnering and financials 2023-11-16 08:33 Regulatory

Stockholm, 16 November 2023. Asarina Pharma AB (publ., “Asarina” or “the Company”) today provides an update on its partnering activities...

Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023) 2023-08-23 08:30 Regulatory Interim

(Stockholm, 23 August 2023) Asarina Pharma today releases its First Half-Year Report for 2023. In addition to the financial statements for H1/2023, the...

Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders 2023-05-23 09:02 Regulatory

Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) 2023-05-22 11:15 Regulatory

The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...

Asarina Pharma’s positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America 2023-05-05 13:33

The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...

Asarina Pharma AB (publ) releases Annual Report 2022 2023-04-28 20:30 Regulatory Annual

The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...

NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL) 2023-04-18 10:39 Regulatory

NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...

Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome 2023-04-01 14:20 Regulatory

THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...

Previous Next